Lenvatinib outperforms sorafenib in treating hepatocellular carcinoma
Lenvatinib, a medication used to treat hepatocellular carcinoma (HCC), shows superior effectiveness compared to sorafenib in real-world conditions, according to a study. Specifically, patients treated with Lenvatinib demonstrated better overall survival, prolonged progression-free survival, and higher response rates.
The study employed a comprehensive methodology involving the retrieval of pertinent literature from reputable databases such as PubMed, Embase, Web of Science, and Cochrane Library spanning from January 1, 2000, to June 25, 2022. The analysis incorporated data from 9 single-arm studies and 6 comparative studies.
The results of the meta-analysis unveiled several notable findings. Lenvatinib demonstrated a statistically significant advantage over sorafenib in terms of overall survival (OS), progression-free survival, objective response rate, and disease control rate.
The study also highlighted that patients treated with lenvatinib experienced a higher incidence of hypertension when compared to those treated with sorafenib. No significant disparity was observed in the occurrence of hand-foot syndrome between the two treatment options.
Reference
Hua X, Yin Z, Liang J, et al. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study. Eur J Gastroenterol Hepatol. 2023;doi: 10.1097/MEG.0000000000002668. Epub ahead of print. PMID: 37942731.
